 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Weekly PCC regimen (paclitaxel + carboplatin + cetuximab) can be used for patients who are not suitable for EXTREME regimen to treat recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC)

Front Oncol: Weekly PCC regimen (paclitaxel + carboplatin + cetuximab) can be used for patients who are not suitable for EXTREME regimen to treat recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC)

 Last Update: 2021-11-12
 Source: Internet
 Author: User

Tags

cell pellet

7 11 propane

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

For most patients with recurrent and / or metastatic head and neck squamous cell carcinoma ( R/M-HNSCC ), chemotherapy is the main treatment
.

For more than ten years, cetuximab combined with platinum - fluorouracil regimen (EXTREME) has been the standard treatment regimen

For most patients with recurrent and / or metastatic head and neck squamous cell carcinoma ( R/M-HNSCC ), chemotherapy is the main treatment

The study reviewed the medical records of all patients who received paclitaxel, carboplatin, and cetuximab (PCC) at the institution .
The selection criteria are : first - line R/M-HNSCC treatment of oral cavity, oropharynx, hypopharynx or larynx is not suitable for local treatment, not suitable for cisplatin and / or 5-FU , ECOG-PS: 0-2 .
PCC includes paclitaxel 80 mg/m2, carboplatin AUC 2 and cetuximab.
The initial dose is 400 mg/m2, and then 250 mg/m2.
It is administered for a total of 16 cycles per week.
Cetuximab is maintained .
The primary endpoint is overall survival (OS), and the secondary endpoints are overall response rate (ORR), progression-free survival (PFS) and safety .

The study reviewed the medical records of all patients who received paclitaxel, carboplatin, and cetuximab (PCC) at the institution .

The selection criteria are : first - line R/M-HNSCC treatment of oral cavity, oropharynx, hypopharynx or larynx is not suitable for local treatment, not suitable for cisplatin and / or 5-FU , ECOG-PS: 0-2 .
PCC includes paclitaxel 80 mg/m2, carboplatin AUC 2 and cetuximab.
The initial dose is 400 mg/m2, and then 250 mg/m2.
It is administered for a total of 16 cycles per week.

2010 years .

Twenty-nine patients (48%) had an ECOG-PS of 0-1 at the beginning of treatment, and 31 patients (52%) had an ECOG-PS of 2

Thirty patients (50%) showed grade III-IV toxicity

toxicity

Toxicity toxicity

The ORR of PCC treatment was 43.

3% (95% CI: 30.

The ORR of PCC treatment was 43.

Efficacy evaluation

Efficacy assessment Efficacy assessment

The median follow-up time was 35.
7 months (IQR 28.
6-48.
8), the median OS was 11.
7 months (95% CI: 7.
5-14.
8), and the median PFS was 5.
8 months (95% CI: 4.
5-7.
2)
.

The median follow-up time was 35.

PFS

PFS PFS

Among patients with an ECOG-PS of 0-1 (ie 29 patients), the median OS was 14.
8 months (95% CI: 12.
2-21.
7), and the median PFS was 7.
1 months (95% CI: 6.
3-9.
0 Month)
.

The median OS of 2 patients with ECOG-PS (ie 31 patients) was 7.

Among patients with an ECOG-PS of 0-1 (ie 29 patients), the median OS was 14.

OS OS

In summary, studies have shown that for R/M-HNSCC that is not suitable for EXTREME treatment, the weekly PCC regimen is an optional regimen
.

In summary, studies have shown that for R/M-HNSCC
that is not suitable for EXTREME treatment, the weekly PCC regimen is an optional regimen .
In summary, the research shows that the research shows that it is not suitable, and the research shows that it is not suitable for EXTREME treatment.
For R/M-HNSCC
that is not suitable for EXTREME treatment, the PCC program of weekly treatment is an optional program .
R/M-HNSCC treated with EXTREME regimen, PCC regimen with weekly treatment is an optional regimen
.

Original source:

Carinato H, Burgy M, Ferry R, et al.
(2021) Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients.
Front.
Oncol.
11:714551.
doi: 10.
3389/fonc.
2021.
714551 Carinato H, Burgy M, Ferry R, et al.
(2021) Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and / or Metastatic Squamous Head and Neck for Patients Ineligible Journal of the Cell-Based to Cisplatin Chemotherapy: A the Retrospective .
.
Monocentric Study in Patients 60 Front Oncol.
11:.
714 551 DOI:.
10.
3389 / fonc.
2021.
714551 in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.